Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detectedMarc Suárez‐Calvet, Natàlia Vilor‐Tejedor, Grégory Operto et al.|EMBO Molecular Medicine|2020Cited by 411
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's diseaseJoel Simrén, Nicholas J. Ashton, Antoine Leuzy et al.|Alzheimer s & Dementia|2021Cited by 354
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s diseaseMarta Milà‐Alomà, Kaj Blennow, Nicholas J. Ashton et al.|Nature Medicine|2022Cited by 349
Biomarker modeling of Alzheimer’s disease using PET-based Braak stagingJoseph Therriault, Pedro Rosa‐Neto, Tharick A. Pascoal et al.|Nature Aging|2022Cited by 300
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Pedro Rosa‐Neto, Marie Vermeiren et al.|JAMA Neurology|2022Cited by 261